314 related articles for article (PubMed ID: 30643127)
1. Anti-CRISPR-mediated control of gene editing and synthetic circuits in eukaryotic cells.
Nakamura M; Srinivasan P; Chavez M; Carter MA; Dominguez AA; La Russa M; Lau MB; Abbott TR; Xu X; Zhao D; Gao Y; Kipniss NH; Smolke CD; Bondy-Denomy J; Qi LS
Nat Commun; 2019 Jan; 10(1):194. PubMed ID: 30643127
[TBL] [Abstract][Full Text] [Related]
2. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type II Anti-CRISPR Proteins.
Hwang S; Maxwell KL
J Mol Biol; 2023 Apr; 435(7):168041. PubMed ID: 36893938
[TBL] [Abstract][Full Text] [Related]
3. Efficient Genome Engineering of a Virulent Klebsiella Bacteriophage Using CRISPR-Cas9.
Shen J; Zhou J; Chen GQ; Xiu ZL
J Virol; 2018 Sep; 92(17):. PubMed ID: 29899105
[No Abstract] [Full Text] [Related]
4. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
5. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells.
Lin P; Qin S; Pu Q; Wang Z; Wu Q; Gao P; Schettler J; Guo K; Li R; Li G; Huang C; Wei Y; Gao GF; Jiang J; Wu M
Mol Cell; 2020 Jun; 78(5):850-861.e5. PubMed ID: 32348779
[TBL] [Abstract][Full Text] [Related]
7. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
[TBL] [Abstract][Full Text] [Related]
8. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
[TBL] [Abstract][Full Text] [Related]
9. Rational designs of in vivo CRISPR-Cas delivery systems.
Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
[TBL] [Abstract][Full Text] [Related]
10. The Discovery, Mechanisms, and Evolutionary Impact of Anti-CRISPRs.
Borges AL; Davidson AR; Bondy-Denomy J
Annu Rev Virol; 2017 Sep; 4(1):37-59. PubMed ID: 28749735
[TBL] [Abstract][Full Text] [Related]
11. Widespread anti-CRISPR proteins in virulent bacteriophages inhibit a range of Cas9 proteins.
Hynes AP; Rousseau GM; Agudelo D; Goulet A; Amigues B; Loehr J; Romero DA; Fremaux C; Horvath P; Doyon Y; Cambillau C; Moineau S
Nat Commun; 2018 Jul; 9(1):2919. PubMed ID: 30046034
[TBL] [Abstract][Full Text] [Related]
12. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells.
Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G
Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565
[TBL] [Abstract][Full Text] [Related]
13. Keeping crispr in check: diverse mechanisms of phage-encoded anti-crisprs.
Trasanidou D; Gerós AS; Mohanraju P; Nieuwenweg AC; Nobrega FL; Staals RHJ
FEMS Microbiol Lett; 2019 May; 366(9):. PubMed ID: 31077304
[TBL] [Abstract][Full Text] [Related]
14. Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect.
Chuang YF; Phipps AJ; Lin FL; Hecht V; Hewitt AW; Wang PY; Liu GS
Cell Mol Life Sci; 2021 Mar; 78(6):2683-2708. PubMed ID: 33388855
[TBL] [Abstract][Full Text] [Related]
15. Types I and V Anti-CRISPR Proteins: From Phage Defense to Eukaryotic Synthetic Gene Circuits.
Yu L; Marchisio MA
Front Bioeng Biotechnol; 2020; 8():575393. PubMed ID: 33102460
[TBL] [Abstract][Full Text] [Related]
16. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
17. A revolutionary tool: CRISPR technology plays an important role in construction of intelligentized gene circuits.
Zhou Q; Zhan H; Liao X; Fang L; Liu Y; Xie H; Yang K; Gao Q; Ding M; Cai Z; Huang W; Liu Y
Cell Prolif; 2019 Mar; 52(2):e12552. PubMed ID: 30520167
[TBL] [Abstract][Full Text] [Related]
18. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
19. Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review).
Alagoz M; Kherad N
Int J Mol Med; 2020 Aug; 46(2):521-534. PubMed ID: 32467995
[TBL] [Abstract][Full Text] [Related]
20. Conversion Tract Analysis of Homology-Directed Genome Editing Using Oligonucleotide Donors.
Kan Y; Hendrickson EA
Methods Mol Biol; 2019; 1999():131-144. PubMed ID: 31127573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
